¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¾à±¹ ½ÃÀå ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ¾à±¹ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2Á¶ 600¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È CAGR 7.3%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ¿Â¶óÀÎ ¾à±¹ ¼ºñ½ºÀÇ ½ÃÀå ħÅõÀ² Áõ°¡, ¼¼°è ¼Ò¸Å¾÷üµéÀÇ ½ÃÀå ÁøÃâÀÌ ÁÖ¿ä ¼ºÀå µ¿·ÂÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ½ÃÀå Âü¿©ÀÚµéÀÇ Áö¿ª ³» ÀÔÁö °È¸¦ À§ÇÑ ÅõÀÚ Áõ°¡, ±â¾÷ °£ Á¦ÈÞ, ÆíÀǼº°ú ºñ¿ë Àý°¨À» Á¦°øÇÏ´Â ¿Â¶óÀÎ ¾à±¹ ¼ºñ½º µµÀÔ Áõ°¡, OTC ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇÑ »ç°í ¹ß»ý·ü Áõ°¡, ÁÖ·Î Áø´Ü ¹× ¿µ»ó ±â¼ú Çâ»óÀ¸·Î ÀÎÇÑ ÀÇ·á¿ë ÀǾàǰ ºÐ¾ßÀÇ ¼ºÀåÀº ¿¹Ãø ±â°£ µ¿¾È Å« ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇÑ ÀÇ·á¿ë ÀǾàǰ ºÐ¾ßÀÇ ¼ºÀåÀº ¿¹Ãø ±â°£ µ¿¾È Å« ¼ºÀå ±âȸ¸¦ âÃâÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
ÇÁ·Î¼¼½º ¹× ¼ºñ½º Á¦°ø °È¸¦ À§ÇÑ Ã·´Ü ±â¼ú °³¹ß, ¾à±¹ ¾÷°è ÁøÀÔÀÚ¸¦ À§ÇØ °³¹ßµÈ ´Ù¾çÇÑ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀÇ °¡¿ë¼º, ePharmacy ¼ºñ½ºÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ½º¸¶Æ®Æù ´Ü¸»±âÀÇ º¸±Þµµ ÀÌ ½ÃÀåÀÇ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷ °£ÀÇ Çù¾÷, ¿Â¶óÀÎ ¾à±¹ÀÇ µðÁöÅРDzÇÁ¸°Æ® È®´ë, ¼¼°è ÀÔÁö °È¿¡ ÁÖ·ÂÇÏ´Â ¸¹Àº ½ÃÀå Âü¿©Àڵ鵵 ÀÌ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
¾à±¹ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Á¦Ç°º°·Î´Â ¾Ï, ´ç´¢º´, ½ÉÇ÷°üÁúȯ µî ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ó¹æ¾à ºÐ¾ß°¡ ¼¼°è ¾à±¹ »ê¾÷À» Áö¹èÇϸç 2024³â ¸ÅÃâ Á¡À¯À²ÀÇ 80% ÀÌ»óÀ» Â÷ÁöÇß½À´Ï´Ù.
- OTC ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ¼Ò¸Å ¾à±¹ ºÐ¾ß´Â ¿©·¯ ¼¼°è ¼Ò¸Å ±â¾÷ÀÇ ¾à±¹ »ç¾÷ ÁøÃâ, ÁÖ¿ä ±â¾÷ÀÌ ¿î¿µÇÏ´Â ¹æ´ëÇÑ ¼Ò¸Å ¾à±¹ ¸ÅÀå ³×Æ®¿öÅ©, ¿Â¶óÀÎ ¼Ò¸Å ¾à±¹ÀÇ ¼ºÀåÀ¸·Î ÀÎÇØ ¾à±¹ ¾÷°è¿¡¼ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- e-¾à±¹ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» °æÇèÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì´Â 2024³â 50% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇϸç Àü ¼¼°è ¾à±¹ »ê¾÷À» Áö¹èÇß½À´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ª¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ´Ù¾çÇÑ Á¦¾àȸ»ç¿Í ƯÈ÷ ¹Ì±¹¿¡¼ ¿©·¯ Áö¿ª¿¡ ¼ºñ½º¸¦ Á¦°øÇÏ´Â ´ë±Ô¸ð ¼Ò¸Å ¾à±¹ üÀο¡ ±âÀÎÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¾à±¹ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¾à±¹ ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ¾à±¹ ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
- Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
- ¾à±¹ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¾à±¹ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(Á¦Ç°º°, 2018-2030³â)
- ó¹æ
- OTC
Á¦5Àå ¾à±¹ ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®
- À¯Çü ºÎ¹® ´ë½Ãº¸µå
- ¾à±¹ ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¾à±¹ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(À¯Çüº°, 2018-2030³â)
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
- ±âŸ
Á¦6Àå ¾à±¹ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª ½ÃÀå ´ë½Ãº¸µå
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
- Áö¿ªº° ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦7Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷/°æÀï ºÐ·ù
- º¥´õ »óȲ
- ±â¾÷ °³¿ä
- CVS Health
- Boots Walgreens
- Walmart Inc.
- The Kroger Co.
- Rite Aid Corp.
- MCKESSON CORPORATION
- Well Pharmacy
- Humana
- Matsumotokiyoshi Co., Ltd.
- Apollo Pharmacy
- MedPlusMart.com
- Amazon
ksm 25.06.26
Pharmacy Market Growth & Trends:
The global pharmacy market size is anticipated to reach USD 2.06 trillion by 2030 and is anticipated to expand at a CAGR of 7.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, increasing market penetration of online pharmacy services, and the entry of global retail companies into this market are primarily driving the growth.
Increasing investments by key market participants in improving presence across various regions, collaborations among companies, and rising adoption of online pharmacy services that offer convenience and cost savings are expected to fuel further growth of this market. The growing incident rate of accidents leading to higher demand for OTC drugs and the growth experienced by the prescription medicine segment, primarily due to enhanced diagnostic technologies and imaging techniques, are likely to develop strong growth opportunities over the forecast period.
Adoption of advanced technologies for enhanced processes and service delivery, availability of various software solutions developed for pharmacy industry participants, and increasing ubiquity of smartphone devices, which facilitates the growth of ePharmacy services, also contribute to the advancements experienced by this market. Collaborations among key companies, the growing digital footprint of online pharmacies, and the focus of numerous key market participants on enhancing global presence also influence this market.
Pharmacy Market Report Highlights:
- On the basis of products, the prescription segment dominated the global pharmacy industry and accounted for over 80% of the revenue share in 2024, owing to the rising occurrence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases.
- The OTC segment is projected to experience the fastest growth over the forecast period.
- The retail pharmacy segment held the largest revenue share of the pharmacy industry, owing to the entry of multiple global retail companies in the pharmacy business, a vast network of retail pharmacy stores operated by key players, and the growth experienced by online retail pharmacy.
- The ePharmacy segment is anticipated to experience the fastest growth over the forecast period.
- North America dominated the global pharmacy industry with a revenue share of more than 50% in 2024, owing to various pharmaceutical manufacturing companies operating in the region and large retail pharmacy chains providing services across multiple locations, especially in the U.S.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product segment
- 1.2.2. Type segment
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Type outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Pharmacy Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Pharmacy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
Chapter 4. Pharmacy Market: Product Estimates & Trend Analysis
- 4.1. Product Segment Dashboard
- 4.2. Pharmacy Market: Product Movement Analysis
- 4.3. Global Pharmacy Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Prescription
- 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. OTC
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Pharmacy Market: Type Estimates & Trend Analysis
- 5.1. Type Segment Dashboard
- 5.2. Pharmacy Market: Type Movement Analysis
- 5.3. Global Pharmacy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 5.4. Hospital Pharmacy
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Retail Pharmacy
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2. Chain
- 5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3. Independent
- 5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.4. Others
- 5.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. ePharmacy
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Others
- 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Pharmacy Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Dashboard
- 6.2. Regional Market Share Analysis, 2024 & 2030
- 6.3. Continuous bioprocessing market by Region: Key Takeaways
- 6.4. North America
- 6.4.1. U.S.
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework/ reimbursement structure
- 6.4.1.3. Competitive scenario
- 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Canada
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework/ reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. Mexico
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework/ reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Europe
- 6.5.1. UK
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Germany
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. France
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Italy
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework/ reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.5. Spain
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Regulatory framework/ reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.6. Norway
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Regulatory framework/ reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.7. Sweden
- 6.5.7.1. Key country dynamics
- 6.5.7.2. Regulatory framework/ reimbursement structure
- 6.5.7.3. Competitive scenario
- 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.8. Denmark
- 6.5.8.1. Key country dynamics
- 6.5.8.2. Regulatory framework/ reimbursement structure
- 6.5.8.3. Competitive scenario
- 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Asia Pacific
- 6.6.1. Japan
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. China
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. India
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework/ reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.4. Australia
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework/ reimbursement structure
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.5. South Korea
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework/ reimbursement structure
- 6.6.5.3. Competitive scenario
- 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.6. Thailand
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework/ reimbursement structure
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Latin America
- 6.7.1. Brazil
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. Argentina
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8. MEA
- 6.8.1. South Africa
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Regulatory framework/ reimbursement structure
- 6.8.1.3. Competitive scenario
- 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.2. Saudi Arabia
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework/ reimbursement structure
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.3. UAE
- 6.8.3.1. Key country dynamics
- 6.8.3.2. Regulatory framework/ reimbursement structure
- 6.8.3.3. Competitive scenario
- 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.4. Kuwait
- 6.8.4.1. Key country dynamics
- 6.8.4.2. Regulatory framework/ reimbursement structure
- 6.8.4.3. Competitive scenario
- 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. Key company heat map analysis, 2024
- 7.4. Company Profiles
- 7.4.1. CVS Health
- 7.4.1.1. Company overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Boots Walgreens
- 7.4.2.1. Company overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Walmart Inc.
- 7.4.3.1. Company overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. The Kroger Co.
- 7.4.4.1. Company overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Rite Aid Corp.
- 7.4.5.1. Company overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. MCKESSON CORPORATION
- 7.4.6.1. Company overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. Well Pharmacy
- 7.4.7.1. Company overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. Humana
- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Matsumotokiyoshi Co., Ltd.
- 7.4.9.1. Company overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
- 7.4.10. Apollo Pharmacy
- 7.4.10.1. Company overview
- 7.4.10.2. Financial performance
- 7.4.10.3. Product benchmarking
- 7.4.10.4. Strategic initiatives
- 7.4.11. MedPlusMart.com
- 7.4.11.1. Company overview
- 7.4.11.2. Financial performance
- 7.4.11.3. Product benchmarking
- 7.4.11.4. Strategic initiatives
- 7.4.12. Amazon
- 7.4.12.1. Company overview
- 7.4.12.2. Financial performance
- 7.4.12.3. Product benchmarking
- 7.4.12.4. Strategic initiatives